Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 8/20 | 0.61 |
| ▸ | CCR5 | P51681 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032049 | 1.00 | CCR2 (0.61) | CCR2CCR5LMNAKCNH2PDE10A | |
| SCHEMBL15032057 | 0.89 | CCR2 (0.48) | CCR2CCR5KCNH2USP2PKM | |
| SCHEMBL12184078 | 0.84 | CCR2 (0.76) | CCR2CCR5LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15032052 | 0.82 | CCR2 (0.71) | CCR2CCR5LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14948792 | 0.82 | CCR2 (0.64) | CCR2CCR5LMNAKCNH2 | |
| SCHEMBL14945908 | 0.81 | CCR2 (0.79) | CCR2CCR5LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL12184105 | 0.81 | CCR2 (0.78) | CCR2CCR5LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL15032053 | 0.81 | CCR2 (0.44) | CCR2CCR5LMNA | |
| SCHEMBL14945890 | 0.80 | CCR2 (0.66) | CCR2CCR5LMNAKCNH2 | |
| SCHEMBL14945892 | 0.80 | CCR2 (0.66) | CCR2CCR5LMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721025-B1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | CCR2, CCRL2, CXCR2 | CCR2 1/4885CCR5 6/4885LMNA 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.